Fibricor

Fibricor is a brand name of fenofibric acid, approved by the FDA in the following formulation(s):

FIBRICOR (fenofibric acid - tablet; oral)

• 
  Manufacturer: AR HOLDING CO INC
  
  Approval date: August 14, 2009
  
  Strength(s): 105MG ^[RLD], 35MG
  

Has a generic version of Fibricor been approved?

No. There is currently no therapeutically equivalent version of Fibricor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fibricor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methods of use of fenofibric acid
  Patent 7,569,612
  Issued: August 4, 2009
  Inventor(s): Arnold; Kristin Anne & Feng; Hengsheng
  Assignee(s): Mutual Pharmaceutical Company, Inc.
  Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
  
  Patent expiration dates:
  
  
  • August 20, 2027
    
    ✓ 
    Patent use: ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS
  
  



• 
  Methods of use of fenofibric acid
  Patent 7,741,373
  Issued: June 22, 2010
  Inventor(s): Arnold; Kristin Anne & Feng; Hengsheng
  Assignee(s): Mutual Pharmacuetical Company, Inc.
  Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
  
  Patent expiration dates:
  
  
  • August 20, 2027
    
    ✓ 
    Patent use: ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA
  
  



• 
  Methods of use of fenofibric acid
  Patent 7,741,374
  Issued: June 22, 2010
  Inventor(s): Arnold; Kristin Anne & Feng; Hengsheng
  Assignee(s): Mutual Pharmaceutical Company, Inc.
  Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
  
  Patent expiration dates:
  
  
  • August 20, 2027
    
    ✓ 
    Patent use: ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS
  
  
  
  • August 20, 2027
    
    ✓ 
    Patent use: ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
  
  



• 
  Methods of use of fenofibric acid
  Patent 7,915,247
  Issued: March 29, 2011
  Inventor(s): Arnold; Kristin Anne & Feng; Hengsheng
  Assignee(s): Mutual Pharmaceutical Company, Inc.
  Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
  
  Patent expiration dates:
  
  
  • August 20, 2027
    
    ✓ 
    Patent use: ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA
  
  
  
  • August 20, 2027
    
    ✓ 
    Patent use: ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
  
  
  
  • August 20, 2027
    
    ✓ 
    Patent use: ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS
  
  

See also...

• Fibricor Consumer Information (Wolters Kluwer)
• Fibricor Consumer Information (Cerner Multum)
• Fibricor Advanced Consumer Information (Micromedex)
• Fenofibric Acid Consumer Information (Wolters Kluwer)
• Fenofibric Acid Delayed-Release Capsules Consumer Information (Wolters Kluwer)
• Fenofibric acid Consumer Information (Cerner Multum)
• Fenofibric acid Advanced Consumer Information (Micromedex)